Nabla Bio

Nabla Bio reports experimental validation of JAM-designed antibodies across seven disclosed targets and one undisclosed target, with binding, selectivity, early developability and target-specific functional assays.

Nabla Bio has active AI protein-design collaborations with major pharmaceutical companies including Takeda, AstraZeneca and Bristol Myers Squibb, but patient-level or commercial therapeutic impact remains early.

Nabla Bio has active AI protein-design collaborations with major pharmaceutical companies including Takeda, AstraZeneca and Bristol Myers Squibb, but patient-level or commercial therapeutic impact remains early.

Nabla Bio develops Joint Atomic Modeling for de novo antibody design and reports experimental validation across difficult targets with high hit rates and drug-like properties.

Nabla Bio develops Joint Atomic Modeling for de novo antibody design and reports experimental validation across difficult targets with high hit rates and drug-like properties.

Nabla Bio developed Joint Atomic Modeling (JAM), an AI protein-design system that designs high-quality lead antibodies de novo from target protein sequence and/or structure and experimentally validated the designs across multiple therapeutic applications.

Nabla Bio announced a second multi-year Takeda research agreement in October 2025 with double-digit millions in contractual upfront and research-cost payments, extending JAM design across early-stage development programs.

Nabla Bio combines AI, protein design and proprietary wet-lab biology, is revenue-generating and works with several major pharmaceutical partners.

Nabla Bio combines AI, protein design and proprietary wet-lab biology, is revenue-generating and works with several major pharmaceutical partners.

Nabla describes JAM as multimodal generative modeling over protein sequence and structure data, conditioned on partial target or epitope context; mammalian-system measurements of binding, developability and cellular/in-vivo function feed its integrated modeling and experimental data workflows.

Protein language modeling, structure prediction and generative design skills transfer broadly within biotech AI, while antibody and therapeutic-domain expertise limit full cross-market portability.

Protein language modeling, structure prediction and generative design skills transfer broadly within biotech AI, while antibody and therapeutic-domain expertise limit full cross-market portability.